VSV-Pseudovirus_SARS-CoV-2 Alpha Luciferase, ReVacc Scientific

Supplier: ReVacc Scientific

L1X97-200UL L1X97-1ML
76519-264EA 2331.68 USD
76519-264 76519-262
VSV-Pseudovirus_SARS-CoV-2 Alpha Luciferase, ReVacc Scientific
Vectors, Plasmids, Libraries and Inserts
This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry spike protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations identified in variant of B.1.1.7 (Alpha strain), including: ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. The spike protein has a 18-aa cytoplasmic tail truncation for optimal infection

Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See the titration result showing the undiluted pseudovirus generates signal over 1000-fold higher than uninfected control (cell alone as background). The neutralizing activity of two control mAbs, including one published (Science, 2020: 369, p643) was tested by using this pseudotyped virus.

As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Applications:
•Anti-SARS-CoV-2 neutralizing antibody screening at high throughput
•Anti-SARS-CoV-2 drug screening at high throughput
•SARS-CoV-2 pseudovirus transduction of target cells for viral entry and functional studies

See suggested protocol to use this product.

Packaging: Shipping with dry ice. Require –80 °C storage. Multiple freeze/thaw cycles will reduce its sensitivity. Recommend only 1 cycle. Aliquot after the first thaw.

Caution: Handle it in biosafety cabinet in BSL-2. Contacted tips and tubes should be decontaminated by 10% disinfecting bleach. For research use only.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR